Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Sorafenib for the treatment of hepatocellular carcinoma : a single-centre real-world study
Avtorji:ID Hanžel, Jurij (Avtor)
ID Božič, Tajda (Avtor)
ID Štabuc, Borut (Avtor)
ID Janša, Rado (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://content.sciendo.com/view/journals/raon/54/2/article-p233.xml
 
.pdf PDF - Predstavitvena datoteka, prenos (583,71 KB)
MD5: 5D63BCBB6C7886967726D16ED3234BF1
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Background Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma. Its efficacy in randomised controlled trials was demonstrated in patients with well-preserved liver function and good functional status. In the real-world setting, treatment is often offered to patients outside these criteria. We therefore performed a single-centre real-world cohort study on the efficacy of sorafenib in patients with hepatocellular carcinoma. Patients and methods We identified all patients with hepatocellular carcinoma initiating treatment with sorafenib between January 2015 and January 2018. The primary endpoint was overall survival (OS) since starting sorafenib. Clinical and demographic variables associated with survival were studied. Results The median OS was 13.4 months (95% CI 8.2%18.6). Multivariable Cox%s regression identified worse ECOG performance status (HR 2.21; 95% CI 1.56%3.16; P < 0.0001), Child-Pugh class C (HR 52.4; 95% CI 3.20%859; P = 0.005) and absence of prior locoregional treatment (HR 2.30; 95% CI 1.37%3.86; P = 0.002) to be associated with increased mortality. Conclusions Careful selection of patients for treatment with sorafenib is of paramount importance to optimize outcomes.
Ključne besede:hepatocellular carcinoma, survival, sorafenib
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.06.2020
Založnik:Association of Radiology and Oncology
Leto izida:2020
Št. strani:str. 233-236, XI
Številčenje:Vol. 54, no. 2
Izvor:Ljubljana
PID:20.500.12556/DiRROS-19290 Novo okno
UDK:616-006
ISSN pri članku:1318-2099
DOI:10.2478/raon-2020-0027 Novo okno
COBISS.SI-ID:19073283 Novo okno
Avtorske pravice:by Authors
Opomba:Soavtorji: Tajda Kosir Bozic, Borut Stabuc, Rado Jansa;
Datum objave v DiRROS:12.07.2024
Število ogledov:327
Število prenosov:156
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:hepatocelularni karcinom, preživetje, sorafenib


Nazaj